MAOB and Dyskinesia: Dyskinesia under LE treatment were even more common when patients were younger than 65 years of age, of male sex, with a body weight >75 kg, with a disease duration less then 2 years and an additional treatment with a MAO-B inhibitor or dopamine agonist (Stocchi et al. 2010).